Dr. Henry Miller talks about the dangers from the United States sourcing a majority of active pharmaceutical ingredients, commonly called APIs, from China and other places impacted by the coronavirus, or COVID-19, pandemic. APIs can be considered the “important” component of a pill or medicine. Miller references a 2019 report by the U.S.-China Economic and Security Review Commission that highlights the growing reliance on China for APIs and problems with China’s regulatory and quality control standards. Miller says more oversight and regulation are needed by the U.S. Federal Drug Administration to better monitor Chinese manufacturing of pharmaceutical products.
The John Batchelor Show Talks U.S.-China Pharmaceutical Risk with Dr. Henry Miller
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
